Literature DB >> 6433565

Aspects of the metabolism of valproic acid.

G R Granneman, S I Wang, J M Machinist, J W Kesterson.   

Abstract

The metabolic routes of valproic acid (VPA) were studied by i.p. administration of the mono-unsaturated and hydroxylated metabolites to rats. Conjugation with glucuronic acid was a major metabolic route for VPA and its metabolites. Conjugation with glycine was a minor route for VPA, but was of more importance with the unsaturated metabolites. The hydroxylated metabolites, which were further oxidized to oxo-derivatives and subsequently to the dicarboxylic acids, were not metabolically dehydrated to form unsaturated metabolites. Multiple metabolic pathways, including dehydrogenation, isomerization, hydration, hydroxylation, reduction and epoxidation were inferred from the metabolites obtained after dosage of the unsaturated metabolites. Six dien-VPA metabolites were detected in VPA-treated rats, four of which are present in patients. It was concluded that 3-en-VPA and 4-en-VPA pathways, originating through dehydrogenation, are distinct from the omega- and omega-1-hydroxylation pathways. Enzyme induction from co-administration of phenobarbital caused enhancement of the minor omega-1-oxidation pathway, yet the largest effect on clearance came from increases in glucuronidation. Mitochondrial processes were unaffected, resulting in decreased contribution to the total clearance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433565     DOI: 10.3109/00498258409151426

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  13 in total

1.  The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, co-medication, and the presence of spina bifida.

Authors:  J G Omtzigt; H Nau; F J Los; L Pijpers; D Lindhout
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.

Authors:  T Kondo; K Otani; T Hirano; S Kaneko; Y Fukushima
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

3.  Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels.

Authors:  H Y Yu; Y Z Shen
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

Review 4.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

Review 5.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

7.  Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.

Authors:  S Hadad; M Bialer
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

Review 8.  Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.

Authors:  Ping Wang; Xiao-Qian Lin; Wen-Ke Cai; Gui-Li Xu; Meng-Di Zhou; Mei Yang; Gong-Hao He
Journal:  Eur J Clin Pharmacol       Date:  2017-12-14       Impact factor: 2.953

9.  Delta 2-valproate biotransformation using human liver microsomal fractions.

Authors:  G Fabre; C Briot; E Marti; J P Montseny; M Bourrié; D Massé; Y Berger; J P Cano
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 10.  Metabolism of valproate to hepatotoxic intermediates.

Authors:  T A Baillie
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.